Skip to main content
Decorative image of the AMR Learning Lounge

CDC 2022 Special Report: COVID-19 U.S. Impact on Antimicrobial Resistance

SUMMARY

CDC-collected antimicrobial resistance (AMR) surveillance data shows an increase of multi-drug resistant organisms (MDROs) in US hospitals during the start of the COVID-19 pandemic. Previously, rates of healthcare acquired infections (HAIs) and deaths from MDROs had been declining from 2017 to 2019. However, the CDC special report states that 2020 showed a significant increase in antimicrobial use and difficulty in following infection prevention and control guidance. HAIs and deaths from MDROs rose by 15% from 2019 to 2020.

The CDC study found an increase in the presence of the following MDROs: 
• Carbapenem-resistant Acinetobacter (+78%)
• Antifungal-resistant Candida auris (+60%)*
• Carbapenem-resistant Enterobacterales (+35%)
• Antifungal-resistant Candida (+26%)
• ESBL-producing Enterobacterales (+32%)
• Vancomycin-resistant Enterococcus (+14%)
• Multidrug-resistant P. aeruginosa (+32%)
• Methicillin-resistant Staphylococcus aureus (+13%)

*Candida auris was not included in the hospital-onset rate calculation of 15%.

FEATURED EXPERTS

Centers for Disease Control and Prevention (CDC)


GET STARTED

Download the CDC’s full report in PDF format.

Read time: varies based on section


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


Global solutions

BIOMÉRIEUX EPISEQ®

Provides easy-to-use applications for clinical microbiologists: bacterial and fungal identification, clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

U.S. bioMérieux Solutions

Us solutions

BIOMÉRIEUX EPISEQ®

Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

PUBLISHED BY

Centers for Disease Control and Prevention (CDC)
September 8, 2022


SHARE THIS ARTICLE: